Skip to main
OBIO

OBIO Stock Forecast & Price Target

OBIO Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Orchestra BioMed Hldgs is a biomedical company with two core programs, AVIM Therapy to treat hypertension and Virtue SAB to treat atherosclerotic artery disease. These programs have significant untapped potential and key updates, such as enrollment completion by the end of 3Q26 and FDA approval of a second Breakthrough Device designation, support future market success. With a discounted cash flow analysis-based asset value of $500M and other key financial metrics, we recommend an Overweight rating, with a $10 price target reflecting a potential 12-month market value of the firm at $595M.

Bears say

Orchestra BioMed Hldgs is a biomedical company with limited human clinical data for its products and a history of operating losses. Despite partnering with larger companies, there is no assurance that the FDA will grant approval for any of its devices and commercialization partnerships may be terminated. Additionally, the company will likely need to raise debt or equity funds to complete development and commercialization, which could be difficult depending on market conditions and may be dilutive to stockholders.

OBIO has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orchestra BioMed Holdings Inc (OBIO) Forecast

Analysts have given OBIO a Strong Buy based on their latest research and market trends.

According to 6 analysts, OBIO has a Strong Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orchestra BioMed Holdings Inc (OBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.